Our first journey at Elevation Oncology is the Phase 2 CRESTONE study, leading straight towards our first summit: NRG1 fusions. The tumor-agnostic approach we’ve chosen is non-traditional, but we’ve assembled a team of collaborators capable of blazing the trail and developing the tools and techniques that will smooth the way for the next summits to follow. The first step in any precision oncology journey is genomic testing. These test results become the map that guides not only individual patient treatment decisions but also our path as precision therapeutic developers. That is why we’ve started building a network of partnerships with groups that are on the leading edge of genomic testing for cancer. In July, we announced our first set of partnerships with Ashion Analytics, Caris Life Sciences, Strata Oncology, and Tempus. With the addition of the US Oncology Research STAR network, just announced yesterday, we can now identify NRG1 fusion positive patients from over 400 clinical sites across the US.
There are no active positions available at this time.
